Syndax to Announce Second Quarter 2023 Financial Results and Host Conference Call and Webcast on August 3, 2023

Rhea-AI Summary

Syndax Pharmaceuticals (Nasdaq: SNDX) to Report Q2 2023 Financial Results and Business Update on August 3, 2023 - Syndax Pharmaceuticals, a clinical-stage biopharmaceutical company, will release its second-quarter 2023 financial results and provide a business update on August 3, 2023, after the close of the U.S. financial markets. The management will also host a conference call and live audio webcast at 4:30 p.m. ET on the same day to discuss the results and provide further updates. Access to the webcast and conference call details are available on the Company's website.

WALTHAM, Mass., July 25, 2023 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it will report its second quarter 2023 financial results and provide a business update on Thursday, August 3, after the close of the U.S. financial markets.

In connection with the earnings release, Syndax's management will host a conference call and live audio webcast at 4:30 p.m. ET on Thursday, August 3, 2023, to discuss the Company's financial results and provide a business update.

The live audio webcast and accompanying slides may be accessed through the Events & Presentations page in the Investors section of the Company's website. Alternatively, the conference call may be accessed through the following:

Conference ID: SNDX2Q23
Domestic Dial-in Number: 800-245-3047
International Dial-in Number: 203-518-9765
Live webcast: https://www.veracast.com/webcasts/syndax/events/SNDX2Q23.cfm

For those unable to participate in the conference call or webcast, a replay will be available on the Investors section of the Company's website at www.syndax.com approximately 24 hours after the conference call and will be available for 90 days following the call.

About Syndax

Syndax Pharmaceuticals is a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Highlights of the Company's pipeline include revumenib, a highly selective inhibitor of the menin–KMT2A binding interaction, and axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor.  For more information, please visit www.syndax.com or follow the Company on Twitter and LinkedIn. 

Syndax Contact

Sharon Klahre
Syndax Pharmaceuticals, Inc.
sklahre@syndax.com
Tel 781.684.9827

SNDX-G

View original content:https://www.prnewswire.com/news-releases/syndax-to-announce-second-quarter-2023-financial-results-and-host-conference-call-and-webcast-on-august-3-2023-301884501.html

SOURCE Syndax Pharmaceuticals, Inc.

FAQ

What is the date of Syndax Pharmaceuticals' Q2 2023 financial results release?

Syndax Pharmaceuticals will release its Q2 2023 financial results on August 3, 2023.

Where can I access the live audio webcast and accompanying slides for the Q2 2023 financial results?

The live audio webcast and accompanying slides may be accessed through the Events & Presentations page in the Investors section of the Company's website.

How long will the replay of the conference call and webcast be available?

The replay will be available on the Investors section of the Company's website at www.syndax.com for 90 days following the call.